IL295360A - Composition and method of mrna vaccines against novel coronavirus infection - Google Patents
Composition and method of mrna vaccines against novel coronavirus infectionInfo
- Publication number
- IL295360A IL295360A IL295360A IL29536022A IL295360A IL 295360 A IL295360 A IL 295360A IL 295360 A IL295360 A IL 295360A IL 29536022 A IL29536022 A IL 29536022A IL 295360 A IL295360 A IL 295360A
- Authority
- IL
- Israel
- Prior art keywords
- composition
- mrna
- orf
- seq
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 30
- 108700021021 mRNA Vaccine Proteins 0.000 title description 20
- 229940126582 mRNA vaccine Drugs 0.000 title description 19
- 238000002360 preparation method Methods 0.000 title description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 229920000642 polymer Polymers 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 22
- 108700026244 Open Reading Frames Proteins 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 239000002105 nanoparticle Substances 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 15
- 239000004472 Lysine Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 241001678559 COVID-19 virus Species 0.000 claims description 11
- 108020004705 Codon Proteins 0.000 claims description 10
- -1 cationic lipid Chemical class 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 208000025721 COVID-19 Diseases 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 6
- 229930185560 Pseudouridine Natural products 0.000 claims description 6
- 239000006199 nebulizer Substances 0.000 claims description 6
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 5
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 4
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 4
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 3
- 101710172711 Structural protein Proteins 0.000 claims description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920002477 rna polymer Polymers 0.000 claims description 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 2
- 108091081024 Start codon Proteins 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 229940096437 Protein S Drugs 0.000 description 31
- 101710198474 Spike protein Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 29
- 229960005486 vaccine Drugs 0.000 description 21
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 20
- 241000711573 Coronaviridae Species 0.000 description 15
- 239000000969 carrier Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 7
- 101710139375 Corneodesmosin Proteins 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 235000014304 histidine Nutrition 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229920001432 poly(L-lactide) Polymers 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000008904 Betacoronavirus Species 0.000 description 5
- 101150008942 J gene Proteins 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 235000019766 L-Lysine Nutrition 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010185 immunofluorescence analysis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000032163 Emerging Communicable disease Diseases 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241001678561 Sarbecovirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NFEXJLMYXXIWPI-JXOAFFINSA-N 5-Hydroxymethylcytidine Chemical compound C1=C(CO)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NFEXJLMYXXIWPI-JXOAFFINSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241001521135 Fringilla coelebs Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000900206 Hantaan virus (strain 76-118) Envelopment polyprotein Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001678562 Merbecovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 101150056612 PPIA gene Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000282312 Proteles Species 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 101710151532 Replicating protein Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 101000956368 Trittame loki CRISP/Allergen/PR-1 Chemical group 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010569 immunofluorescence imaging Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971834P | 2020-02-07 | 2020-02-07 | |
| US202063058463P | 2020-07-29 | 2020-07-29 | |
| US202063130581P | 2020-12-24 | 2020-12-24 | |
| PCT/US2021/017149 WO2021159118A2 (en) | 2020-02-07 | 2021-02-08 | Composition and method of mrna vaccines against novel coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295360A true IL295360A (en) | 2022-10-01 |
Family
ID=77200778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295360A IL295360A (en) | 2020-02-07 | 2021-02-08 | Composition and method of mrna vaccines against novel coronavirus infection |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12029786B2 (https=) |
| EP (1) | EP4100066A4 (https=) |
| JP (1) | JP2023512833A (https=) |
| KR (1) | KR20220143684A (https=) |
| CN (1) | CN115297892A (https=) |
| AU (1) | AU2021216443A1 (https=) |
| BR (1) | BR112022015626A2 (https=) |
| CA (1) | CA3167257A1 (https=) |
| IL (1) | IL295360A (https=) |
| MX (1) | MX2022009688A (https=) |
| WO (1) | WO2021159118A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| WO2021160887A1 (en) * | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| JPWO2021181994A1 (https=) * | 2020-03-10 | 2021-09-16 | ||
| US20230313323A1 (en) * | 2020-03-26 | 2023-10-05 | Ionian Technologies, Llc | Assays for detecting coronavirus disease 2019 (covid-19) |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| EP4334479A4 (en) * | 2021-05-06 | 2025-02-19 | Lu, Shi-Long | DETECTION OF VIRAL VARIANTS |
| JP2024530672A (ja) | 2021-08-11 | 2024-08-23 | アールエヌエーイミューン、インコーポレイテッド | 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法 |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| CN118475371A (zh) * | 2021-09-22 | 2024-08-09 | 圣诺制药公司 | 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂 |
| WO2023049814A2 (en) * | 2021-09-22 | 2023-03-30 | Sirnaomics, Inc. | Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index |
| CN113881806A (zh) * | 2021-09-23 | 2022-01-04 | 华南理工大学 | 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒 |
| EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
| WO2023091766A2 (en) * | 2021-11-19 | 2023-05-25 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines |
| AU2022398292A1 (en) * | 2021-11-29 | 2024-06-13 | BioNTech SE | Coronavirus vaccine |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN118556131A (zh) | 2022-01-27 | 2024-08-27 | 爱思开生物科技有限公司 | 用于蛋白质表达的mRNA及其模板 |
| US20250228929A1 (en) * | 2022-04-03 | 2025-07-17 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| DE102023002588A1 (de) * | 2022-06-26 | 2024-01-25 | BioNTech SE | Coronavirus-Impfstoff |
| WO2024002985A1 (en) * | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| KR102832944B1 (ko) * | 2024-12-27 | 2025-07-15 | 대한민국 | 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1270732A1 (en) * | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| SG11201405542UA (en) * | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| CN110520155A (zh) * | 2017-02-28 | 2019-11-29 | 广州纳泰生物医药技术有限公司 | 预防和治疗寨卡病毒感染的rna药物制剂 |
| AU2019275071B2 (en) * | 2018-05-24 | 2022-12-15 | Sirnaomics, Inc. | Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics |
| PH12022551788A1 (en) * | 2020-01-28 | 2024-02-26 | Codagenix Inc | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| US20210316002A1 (en) | 2020-04-14 | 2021-10-14 | Ut-Battelle, Llc | Compositions and methods for drug delivery and treating viral infections |
| BR112022024662A2 (pt) | 2020-06-03 | 2023-04-04 | Regeneron Pharma | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 |
| EP4204015A4 (en) | 2020-08-31 | 2025-01-01 | The Board of Trustees of the Leland Stanford Junior University | Systems and methods for producing rna constructs with increased translation and stability |
| US20250213679A1 (en) | 2020-10-02 | 2025-07-03 | Celsion Corporation | Polynucleotide vaccines and methods of using the same |
| CN115160413B (zh) | 2021-04-06 | 2023-11-14 | 清华大学 | 一种新型冠状病毒疫苗 |
-
2021
- 2021-02-08 US US17/170,876 patent/US12029786B2/en active Active
- 2021-02-08 BR BR112022015626A patent/BR112022015626A2/pt not_active Application Discontinuation
- 2021-02-08 US US17/798,051 patent/US20230108926A1/en not_active Abandoned
- 2021-02-08 EP EP21750867.0A patent/EP4100066A4/en not_active Withdrawn
- 2021-02-08 CN CN202180024212.1A patent/CN115297892A/zh active Pending
- 2021-02-08 WO PCT/US2021/017149 patent/WO2021159118A2/en not_active Ceased
- 2021-02-08 IL IL295360A patent/IL295360A/en unknown
- 2021-02-08 KR KR1020227030556A patent/KR20220143684A/ko not_active Withdrawn
- 2021-02-08 CA CA3167257A patent/CA3167257A1/en active Pending
- 2021-02-08 MX MX2022009688A patent/MX2022009688A/es unknown
- 2021-02-08 JP JP2022548143A patent/JP2023512833A/ja active Pending
- 2021-02-08 AU AU2021216443A patent/AU2021216443A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021159118A3 (en) | 2021-10-28 |
| EP4100066A4 (en) | 2024-05-01 |
| JP2023512833A (ja) | 2023-03-29 |
| KR20220143684A (ko) | 2022-10-25 |
| CA3167257A1 (en) | 2021-08-12 |
| US12029786B2 (en) | 2024-07-09 |
| WO2021159118A2 (en) | 2021-08-12 |
| MX2022009688A (es) | 2022-12-15 |
| CN115297892A (zh) | 2022-11-04 |
| US20230108926A1 (en) | 2023-04-06 |
| US20220040292A1 (en) | 2022-02-10 |
| EP4100066A2 (en) | 2022-12-14 |
| BR112022015626A2 (pt) | 2022-10-11 |
| AU2021216443A1 (en) | 2022-09-08 |
| WO2021159118A8 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12029786B2 (en) | Composition and method of mRNA vaccines against novel coronavirus infection | |
| US11058779B2 (en) | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection | |
| CN115768521B (zh) | 预防和治疗新冠病毒感染引起的严重急性呼吸道感染疾病的RNAi药物组合物及方法 | |
| JP2024503698A (ja) | 変異型株ベースのコロナウイルスワクチン | |
| US20240294580A1 (en) | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines | |
| US12280105B2 (en) | Compositions and methods of mRNA vaccines against novel coronavirus infection | |
| US12280104B2 (en) | Composition and methods for MRNA vaccines against novel omicron coronavirus infections | |
| CN116917470A (zh) | PAN-RAS mRNA癌症疫苗 | |
| CN119866376A (zh) | 编码流感病毒抗原的自扩增rna | |
| KR20230008707A (ko) | 코로나바이러스 치료용 백신 조성물 | |
| WO2023098679A1 (zh) | 预防突变株的新型冠状病毒mRNA疫苗 | |
| US20230218746A1 (en) | Compositions and methods relating to antiviral therapeutics | |
| CN115120608A (zh) | 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用 | |
| CN117642179A (zh) | 流感病毒核酸脂质颗粒疫苗 | |
| WO2025024336A1 (en) | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines | |
| WO2024206843A2 (en) | Compositions including modified coronavirus vaccines and uses thereof | |
| WO2025250938A2 (en) | Respiratory syncytial virus and metapneumovirus vaccines | |
| CN117683790A (zh) | 一种嗜肺军团菌相关抗原的mRNA疫苗及其制备方法与用途 | |
| WO2022219606A1 (en) | Polynucleotides capable of enhanced protein expression and uses thereof |